Melasma - I-Melasma
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Kuyisimo esivamile esibonwa kwabesifazane base-Asia abasanda kweva eminyakeni engu-40. Isilonda esiyindilinga esithombeni siseduze ne-lentigo kune-melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Muva nje, i-laser engu- low-fluence Q-switched Nd:YAG (LFQSNY) isidumile ekwelapheni i-melasma, ikakhulukazi e-Asia. Ukufingqa izifundo ezihlukahlukene bekuyinselele, kodwa i-LFQSNY ibonakala isebenza kahle futhi iphephile ku-melasma uma iqhathaniswa nemithi yokwelapha yendabuko. Kodwa-ke, ezinye izimo ze-mottled hypopigmentation ziye zabikwa njengomphumela oseceleni we-LFQSNY, okungenzeka ngenxa yamandla aphezulu e-laser. Ukusetshenziswa kabi kwe-LFQSNY nakho kungaholela ekwandeni kwesikhumba ngenxa yokuvuvukala, ikakhulukazi esikhumbeni esimnyama.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Izinkinga ze-pigmentation zivame ukutholakala ekunakekelweni okuyinhloko. Izinhlobo ezijwayelekile zokuphazamiseka kwe-hyperpigmentation zihlanganisa post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
I-Melasma ayikwazi ukuxazululwa ngokwelashwa nge-laser isikhathi esithile, njengoba kuyisifo lapho i-pigment ikhiqizwa ngokuqhubekayo. I-Tranxenemic acid isiza ukuthuthukisa ukwehlisa umbala.
○ Ukwelashwa
Kwamanye amazwe (isb. Japan, Korea), i-oral tranexamic acid iyatholakala phezu kwekhawunta futhi iyasebenza. Ukhilimu we-melasma one-tranexamic acid ne-azelaic acid ungaba usizo kancane.
IHydroquinone ingase isetshenziselwe phezulu ekwelapheni i-hyperpigmentation, kodwa i-FDA yamisa imikhiqizo ye-OTC equkethe i-hydroquinone kusukela ngo-2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma